Literature DB >> 10548818

Efficient patient identification strategies for women with osteoporosis.

T A Abbott1, L Mucha, D Manfredonia, E N Schwartz, M L Berger.   

Abstract

The purpose of this analysis was to identify efficient (highest sensitivity at each level of cost) strategies to detect osteoporosis in postmenopausal women. Our study sample consisted of 392 women (age >/=50 yr) who were retirees or active employees of a corporation. The Simple Calculated Osteoporosis Risk Estimation (SCORE) questionnaire was completed, and bone mineral density levels were collected at the forearm using peripheral dual X-ray absorptiometry (pDXA), and at the femoral neck and lumbar spine using central DXA. Osteoporotic women were those with a T-score of -2.5 or less at any one of the three skeletal sites tested. Assumed costs were $5 for SCORE, $35 for pDXA, $120 for DXA at either the hip or spine, and $200 for DXA at both the hip and spine. The analysis indicated that the current "gold standard" is inefficient relative to other strategies investigated. By comparison, a tiered strategy consisting of SCORE, pDXA, and then selective use of DXA at both the hip and spine identified 90% of the women with osteoporosis at a cost of only $106 per woman tested. In choosing among the efficient strategies, decision makers must determine the extent to which they are willing to trade off higher program cost for greater sensitivity.

Entities:  

Mesh:

Year:  1999        PMID: 10548818     DOI: 10.1385/jcd:2:3:223

Source DB:  PubMed          Journal:  J Clin Densitom        ISSN: 1094-6950            Impact factor:   2.963


  2 in total

Review 1.  Prescreening tools to determine who needs DXA.

Authors:  Elliott N Schwartz; Dee M Steinberg
Journal:  Curr Osteoporos Rep       Date:  2006-12       Impact factor: 5.096

2.  Screening for low bone mass with quantitative ultrasonography in a community without dual-energy X-ray absorptiometry: population-based survey.

Authors:  Nan-Ping Yang; Ian Jen; Shao-Yuan Chuang; Shui-Hu Chen; Pesus Chou
Journal:  BMC Musculoskelet Disord       Date:  2006-03-09       Impact factor: 2.362

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.